Real-world study of Oregon's nonmedical psilocybin program shows promise

Study of Oregon's legal mushroom experiment demonstrates promise Oregon was the first state to establish a legalized and regulated psilocybin industry.

Key points

• Those in the study represent only a small fraction of the more than 20, 000 individuals who've gone through Oregon's program since it rolled out regarding three years ago.
• Only a particularly small number had "serious adverse reactions, " according to the analysis published on Wednesday in the medical journal JAMA Network Open.
• Garcia-Romeu notes he has personally spoken with numerous residents from Oregon who have struggled in the aftermath of their psilocybin experience and contacted the Johns Hopkins psychedelic center.
• Korthuis notes his group aims to track a much larger sample of individuals as part of the research initiative, known as the Open Psychedelic Evaluation Nexus, or OPEN.
• Although adults there do have the option of using the drug outside of a supervised setting.), (Colorado has additionally rolled out its own psychedelic program.

New research on the experiences of individuals who took magic mushrooms through Oregon's homegrown psychedelic industry – the first program of its kind in the U.S. – is offering a largely favorable picture. A dose of psilocybin helps smokers quit in new study.

Meanwhile, the study, based on almost 350 individuals who took the drug at state-licensed centers, is the most rigorous analysis yet of the real-world implications of regulated psilocybin, the active ingredient in magic mushrooms.

Most of the participants described their trip as beneficial, and more than half ranked it among the most meaningful experiences of their lives. Meanwhile, the data suggests the program was overall quite safe.

Dr. Todd Korthuis, who led the research team based at Oregon Health & Science University, remarked that initially, even he was skeptical concerning dosing individuals with psilocybin outside of a tightly controlled medical setting.

"The data has swayed me, " he informed NPR. "These results are very reassuring."

Want the latest stories on the science of healthy living? Subscribe to NPR's Health newsletter.

Much of the recent momentum around psychedelics has centered on running drug development trials, with the aim of eventually winning approval from the Food and Drug Administration so that psilocybin, LSD and other substances can be applied to treat mental health conditions.

Psilocybin has a shot at being approved as shortly as next year, based on results from substantial human studies that applied a synthetic form of the drug for hard-to-treat depression. The new Oregon data represents a particularly different pathway.

In 2020, the state's voters approved a nonmedical model for psilocybin, meaning most individuals over 21 can take the drug under the supervision of a facilitator at a designated center, without a prescription or medical referral.

Other scientists involved in psychedelics research were surprised that the real-world results out of Oregon look so promising.

In practice, the number of adverse events is roughly what you'd expect from other psychiatric interventions, notes Balázs Szigeti, a clinical data scientist at the University of California, San Francisco. This person wasn't involved in the study.

"In clinical settings, there are a lot of eyes on the patients, a lot of medical attention, " he notes. "To see that the whole thing did not blow up in this regulated business environment is definitely good news for psilocybin."

Participants' rationale for taking psilocybin varied – curiosity, self-improvement, mental health and trauma were the most common reasons given.

Meanwhile, the average dose was regarding 30 milligrams. It is a bit higher than what tends to be administered in clinical trials.

More than half of individuals in the new report stated their mental health symptoms improved afterward, but Szigeti notes those findings are hard to interpret as the study was uncontrolled and individuals had varying degrees of symptoms at baseline.

Nevertheless, the positive change in mental well-being – another measure employed in the study – is similar to what's documented in studies looking at the effect of meditation, he adds.

Microdosing and tripping on mushrooms is on the rise in U.S.

In terms of safety, the most significant problems were related to behavioral health, not physical health.

For example, one person was transported to the hospital after having a "violent reaction" while on the drug; another afterwards went to the emergency room due to anxiety.

Korthuis notes that the four individuals who had what were classified as "serious adverse reactions" were all trying psilocybin for the first time.

Alongside these incidents were some other concerning data points. One week after their session, three participants remarked they had new thoughts of dying or suicide. That number doubled by the three-month mark.

Plenty of in the study were white and college-educated. Regarding a third had a household income over $200, 000.

Korthuis notes the demographics of their study closely mirror the larger population that has visited the state's licensed psilocybin service centers. It are concentrated in the Portland area.

It's feasible the low number of adverse events may be an "artifact" of who decided to join the study, or how those incidents are noted, notes Albert Garcia-Romeu, a professor of psychiatry and behavioral sciences at Johns Hopkins School of Medicine.

"This is a very small group of people and a rarified sample, " he notes.

" I would say that we really can't generalize based on this study that it's going to be this safe and look this way for everyone, " he adds.

But he's confident the results can be generalized – and that they bode well for the future of a regulated psychedelic industry.

"For whatever reason, psychedelics like psilocybin appear to be cross-cutting and help people revisit a host of issues in their lives, " he notes. "Sometimes people come in for one thing and come out with three others."

In short, real-world study of Oregon' s nonmedical psilocybin program shows promise is the central thread here, and readers can expect follow-up reporting as the picture becomes clearer.